Insulet (NASDAQ:PODD) Upgraded at StockNews.com
StockNews.com upgraded shares of Insulet (NASDAQ:PODD – Free Report) from a hold rating to a buy rating in a research report sent to investors on Monday morning. Other research analysts have also issued research reports about the company. Wells Fargo & Company lifted their target price on Insulet from $305.00 to $322.00 and gave the […]
iRhythm Technologies (NASDAQ:IRTC) Upgraded at StockNews.com
StockNews.com upgraded shares of iRhythm Technologies (NASDAQ:IRTC – Free Report) from a sell rating to a hold rating in a research note released on Monday morning. A number of other equities research analysts have also weighed in on IRTC. Canaccord Genuity Group upped their target price on shares of iRhythm Technologies from $125.00 to $152.00 […]
Tripadvisor (NASDAQ:TRIP) Upgraded by StockNews.com to “Buy” Rating
StockNews.com upgraded shares of Tripadvisor (NASDAQ:TRIP – Free Report) from a hold rating to a buy rating in a research report released on Monday. Several other equities analysts have also commented on TRIP. DA Davidson reiterated a “neutral” rating and issued a $16.00 target price on shares of Tripadvisor in a research note on Thursday, […]
Dynavax Technologies (NASDAQ:DVAX) Upgraded to Buy at StockNews.com
StockNews.com upgraded shares of Dynavax Technologies (NASDAQ:DVAX – Free Report) from a hold rating to a buy rating in a report published on Monday. Several other research firms also recently issued reports on DVAX. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. HC Wainwright […]
CF Industries (NYSE:CF) Stock Rating Upgraded by Bank of America
Bank of America upgraded shares of CF Industries (NYSE:CF – Free Report) from an underperform rating to a neutral rating in a research report sent to investors on Monday, Marketbeat.com reports. Bank of America currently has $84.00 price objective on the basic materials company’s stock. A number of other equities analysts also recently commented on […]
BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Rating Upgraded by Oppenheimer
Oppenheimer upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a market perform rating to an outperform rating in a report issued on Monday, Marketbeat Ratings reports. Oppenheimer currently has $98.00 price target on the biotechnology company’s stock. BMRN has been the subject of a number of other reports. Bank of America lifted their […]
last updated on 27 Feb 09:14